- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00389103
Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)
January 17, 2014 updated by: Sanofi Pasteur, a Sanofi Company
A Phase 1, Placebo-Controlled, Double-Blind Study of the Safety and Immunogenicity of Two Injections of MVA3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Vaccinia Naive Adult Subjects With a History of Atopic Dermatitis (AD)
purpose of this study is to assess the safety and immunogenicity of two MVA smallpox vaccine injections in healthy adults that are 18-35 years of age with a history of mild to moderate Atopic Dermatitis.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, double-blind, placebo-controlled study.
subjects will be randomized to receive investigational vaccine or placebo at a ratio of 3.5:1, MVA3000 to placebo.
All subjects will undergo a screening period, a treatment/observation period during which all subjects will receive injections on study day 0 and study day 28 of investigational vaccine or placebo.
The clinical observation period will be completed at day 56.
A visit will occur at approximately 3 months after the second study injection (study day 118) for additional blood collection and a review of the subject's health status.
Follow-up will be obtained via telephone contacts approximately 6 months after the end of the second injection during the treatment/observation period.
Study Type
Interventional
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87106
- Academic Dermatology Associates
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Texas
-
Austin, Texas, United States, 78759
- Dermresearch, Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 35 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults at least 18 years old and who were born after 1971 with no previous history of smallpox vaccination
- Subjects must be in good general health Female subjects must not be pregnant or lactating and must agree to practice birth control during the course of the study
- Subjects must have a diagnosis of AD by an experienced clinician that includes a history of both major and minor diagnostic criteria
- At the time of screening, the subject must have "mild to moderate" AD.
Exclusion Criteria:
- History or evidence of prior exposure to a vaccinia or MVA- containing product
- known or suspected history of immunodeficiency other than AD
- Known or suspected impairment of major organ function
- Known history or diagnosis of cardiac disease or cerebrovascular disease
- presence of acute, chronic, or active exfoliative skin conditions other than AD, open wounds, or burns.
- Dementia or history of seizures
- Known allergies to MVA or any known components of the vaccine
- transfusion of blood, organ transplantation, or treatment with any blood product
- morbid obesity, or a BMI less than or equal to 18.5
- history of or current drug or alcohol abuse (except nicotine) within the past 6 months or any history of IV drug use
- history of major psychiatric illness except major depression not requiring medical therapy.
- subjects who have participated in another investigational drug or vaccine trial within 30 days of study day 0
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo
|
0.5ml of MVA3000 Smallpox vaccine, administered twice separated by 28 days, subcutaneous injections
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety
Time Frame: Study Completion
|
Study Completion
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Immunogenicity
Time Frame: Study Completion
|
Study Completion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2006
Primary Completion (Actual)
January 1, 2007
Study Completion (Actual)
January 1, 2007
Study Registration Dates
First Submitted
October 16, 2006
First Submitted That Met QC Criteria
October 17, 2006
First Posted (Estimate)
October 18, 2006
Study Record Updates
Last Update Posted (Estimate)
January 22, 2014
Last Update Submitted That Met QC Criteria
January 17, 2014
Last Verified
January 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-249-005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of ScalpUnited States
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
Clinical Trials on MVA (smallpox vaccine)
-
National Institute of Allergy and Infectious Diseases...Completed
-
Sanofi Pasteur, a Sanofi CompanyTerminatedHIV Infections | SmallpoxUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompleted
-
Sanofi Pasteur, a Sanofi CompanyCompleted
-
National Institute of Allergy and Infectious Diseases...Completed
-
Ivan LitvinovTerminatedBasal Cell Carcinoma | Squamous Cell Carcinoma | Non-melanoma Skin CancerCanada
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedYellow Fever | Yellow Fever ImmunisationUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
Bavarian NordicCompleted